A polynucleotide injectable. It doesn't add volume or lift — it works on the skin's repair capacity and barrier. Not FDA-approved for injection in the US.
An injectable containing purified polynucleotides at 20 mg/mL. It doesn't add volume and doesn't lift — it works on the skin's repair capacity. Introduced in 2014 as the first polynucleotide used as a skin booster. Not FDA-approved for injection in the United States.
Published protocols generally use two to four sessions spaced two to four weeks apart, with the effect assessed cumulatively at three to six months. This matters for travel: one trip usually covers one or two sessions, not a full course.
Worth knowing before you read anything else about Rejuran: the Phase III trial most often cited for it — published in the Journal of Korean Medical Science in 2014 — was retracted in 2016 because the manufacturer had funded the study while the paper declared no financial involvement. The treatment is still widely used and later studies exist, but the single most-quoted piece of evidence is no longer citable. Published work since then reports moderate improvements in wrinkle depth, texture and elasticity across small trials, and the overall evidence base remains young.
Rejuran is made from purified salmon DNA, so a documented fish or salmon allergy is a firm reason not to have it. Treatment is generally avoided during pregnancy and breastfeeding, and postponed where there is active infection or inflammation in the area. Tell the clinic about blood thinners, bleeding disorders and autoimmune conditions. Expect redness, small bumps and occasional bruising at injection sites for one to three days.
The first polynucleotide used as a skin booster, introduced in 2014. Studied for skin texture, elasticity and hydration rather than volume or lift.
Works on skin repair capacity rather than resurfacing, so it is often combined with laser rather than used instead of it.
Doesn't lift anything. A polynucleotide injectable studied for skin thickness, wrinkle depth and texture. The most-cited trial for it was retracted in 2016 over undisclosed manufacturer funding; later studies report moderate improvements, but the evidence base is younger than for long-established injectables.
Send your concern, travel dates and budget. A coordinator asks the clinics on your behalf and replies in English with options — including treatments you may not have considered.
General guidance, not medical advice. This page does not describe results you should expect. Outcomes vary and every procedure carries risks that should be discussed with a licensed physician. Treatment suitability is confirmed by the clinic at consultation.
Cleared indications and treatment depths are as published by the device manufacturer; actual depth reached varies with transducer selection, settings and individual anatomy. Comparative statements describe published device specifications, not the relative quality of any clinic or physician.
Where prices are shown, they are ranges drawn from the non-reimbursable treatment costs partner clinics publish under Article 45 of Korea's Medical Service Act. They are not quotes, offers or discounts, and your final price is confirmed by the clinic.
Device and product names are registered trademarks of their respective owners. KRACE and 알앤피티 주식회사 are not affiliated with, endorsed by, or sponsored by any of these companies. Device names are used only to identify treatments offered by partner clinics.
Regulatory statements are current as of August 2026.
KRACE is a healthcare curation and coordination service operated by 알앤피티 주식회사 (RnPT Inc.), registered for foreign patient attraction, intended for patients residing outside Korea. KRACE does not provide medical services and does not charge patients a coordination fee.